



Name Yuh-Pyng Sher
Current Positions Associate Professor, Graduate Institute of Biomedical Sciences, China Medical University
Cancer Center Building 8F, No.6, Hsueh-Shih Road, Taichung, 404, Taiwan

Telephone +886-4-2205-2121 Ext. 7819
E-mail ypsher@mail.cmu.edu.tw; ypsher@gmail.com
E-Portfolio Website http://webap.cmu.edu.tw/TchEportfolio/index_1/ypsher
Personal Website

Education

BS, Department of Medical Technology, College of Medicine, National Taiwan University, Taiwan (1994)
MS, Department of Medical Technology, College of Medicine, National Taiwan University, Taiwan (1996)
PhD, Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taiwan (2006)
Postdoc in Cancer research, China Medical University Hospital, Taiwan (2007)

Expertise

Molecular biology; immunology; target therapy; drug development; cancer vaccine; tumor animal models; inflammation

Research Interests

My research interests are to decipher the mechanism important for cancer metastasis in several cancer types, including lung cancer, triple-negative breast cancer, esophageal squamous cell carcinoma, and pancreatic cancer. We have combined the biochemical approaches, clinical studies, and experimental mice models to address it and develop promising cancer treatments for clinical application.

Selected Grants:

PI:

1. MOST Industry-Academy Collaborative Research Grant. MOST 109-2622-B-039-004 (2020/11/01 ~ 2021/10/31)
2. MOST 108-2314-B-039 -054 -MY3 (2019/08/01 ~ 2022/07/31)
3. The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. Chinese Medicine Research Center. CMRC-CHM-3-1 (2020/01/01 ~ 2020/12/31)

Selected Publications

1. Chou CW, Huang YK, Kuo TT, Liu JP, Sher YP*. An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases. *International Journal of Molecular Sciences* 21:7790. October 21, 2020. **IF=4.556**
2. Sher YP, Chai KM, Chen WC, Shen KY, Chen IH, Lee MH, Chiu FF, Liu SJ*. A polypeptide of tumor-associated antigen L6 with intrinsic adjuvant activity enhances antitumor immunity. *Vaccines* 8:620. October 21, 2020. **IF=4.0866**
3. Lin CC, Huang YK, Cho CF, Lin YS, Lo CC, Kuo TT, Tseng GC, Cheng WC, Chang WC, Hsiao TH, Lai LC, Shih JY, Liu YH, Chao KSC, Hsu JL, Lee PC, Sun X, Hung MC, Sher YP*. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. *Theranostics* 10(24):10925-10939. August 29, 2020. **IF=8.579**

4. Lin YS, Hsieh CY, Kuo TT, Lin CC, Lin CY, and Sher YP* Resveratrol-mediated ADAM9 degradation decreases cancer progression and provides synergistic effects in combination with chemotherapy. American Journal of Cancer Research (in press. 2020). **IF=5.177**
5. Chou CW, Lin CH, Hsiao TH, Lo CC, Huang CC, Sher YP*. Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis. Scientific Reports 9:20403. 31 December, 2019. **IF=3.998**
6. Sher YP§, Lin SI§, Chai KM, Chen IH, Liu SJ*. Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine. American Journal of Cancer Research 9(9):2028-2036. September 15, 2019. **IF=5.177**
7. Sher YP, Lee C, Liu SY, Chen YH, Lee MH, Chiu FF, Leng CH*, Liu SJ*. A therapeutic vaccine targeting HPV E6/E7 with intrinsic Toll-like receptor 2 agonist activity induces antitumor immunity. American Journal of Cancer Research 8(12):2528-2537. November, 2018. **IF=5.177**
8. Lin CY§, Chia-Fong Cho§, Bai ST, Liu JP, Kuo TT, Wang LJ, Lin YS, Lin CC, Lai LC, Lu TP, Hsieh CY, Chu CN, Cheng DC, Sher YP*. ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT. Scientific Reports 7:15108. November, 2017. **IF=3.998**
9. Chiu KL, Kuo TT, Kuok QY, Lin YS, Hua CH, Lin CY, Su PY, Lai LC*, and Sher YP*. ADAM9 enhances CDCP1 protein expression by suppressing miR-218 for lung tumor metastasis. Scientific Reports 5:16426. November 2015. **IF=3.998**
10. Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC*, Sher YP*. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Research 74(18):5229-43. September 2014. **IF=9.727**

Selected Patents

1. ADAM9 inhibitors and the uses thereof. Inventors: **Yuh-Pyng Sher**, Yang-Chang Wu, Juan-Cheng Yang, Ting-Ting Kuo, Chia-Chien Lo. (Taiwan patent (I695000, 2020/6/1 ~ 2038/10/28); EPC/US/China patent application)
2. Rapid efficacy assessment method for lung cancer therapy. Inventors: K Peck, **YP Sher**, PC Yang, JY Shih, CW Wu. US patent #7507534B2
3. PC Kung, K Peck, YS Lee, **YP Sher**, YC Cheng. Phytomics: A Genomic-based Approach to Herbal Compositions. US patent 2003/0207270 A1.